CLINICAL EVALUATION OF NEGGRAM, A NEW ANTIMICROBIAL AGENT: PRELIMINARY REPORT.
D000890:Anti-Infective Agents; D035843:Biomedical Research; D003556:Cystitis; D004351:Drug Resistance; D004352:Drug Resistance, Microbial; D004927:Escherichia coli Infections; D006069:Gonorrhea; D006801:Humans; D007709:Klebsiella; D008297:Male; D009268:Nalidixic Acid; D009287:Naphthyridines; D010600:Pharmacology; D011472:Prostatitis; D011511:Proteus; D011549:Pseudomonas; D011704:Pyelonephritis; D013210:Staphylococcus; D013291:Streptococcus; D014116:Toxicology; D014526:Urethritis; D014552:Urinary Tract Infections
D000890:Anti-Infective Agents; D009287:Naphthyridines; D009268:Nalidixic Acid
ANTI-INFECTIVE AGENTS; CLINICAL RESEARCH; CYSTITIS; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI INFECTIONS; GONORRHEA; KLEBSIELLA; NALIDIXIC ACID; NAPHTHYRIDINES; PHARMACOLOGY; PROSTATITIS; PROTEUS; PSEUDOMONAS; PYELONEPHRITIS; STAPHYLOCOCCUS; STREPTOCOCCUS; TOXICOLOGIC REPORT; URETHRITIS; URINARY TRACT INFECTIONS